Clinical trial
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced…
NCT00169208 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00169208 |
|---|---|
| Title | Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma |
| Official title | An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma. |
| Lead sponsor | Lymphoma Study Association, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab, fludarabine, mitoxantrone |
| Enrollment | 50 |
| Start date | Apr 1, 2001 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 28, 2019 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: